) announced that its biological products and services business -
Sigma Life Science - has launched a novel editing tool Sigma
CRISPRs. CRISPRs are a mammalian genome editing tool appropriate
for screening and exploratory studies. They are inexpensive tools
that can be used for the development of targeted gene
Sigma-Aldrich CRISPRs are obtained from bacterial and archaeal
immune defenses, which guard against invading viruses and foreign
DNA. CRISPRs use customizable RNA-nuclease complexes that allow
introduction of genome edits at a desired site in mammalian
genomes with high efficiency.
Sigma-Aldrich also has an exclusive online bioinformatics tool
where CRISPRs can be custom-designed. It is the only commercial
tool that automatically applies CRISPR/Cas best design practices,
including a minimum requirement of three base-pair mismatches
between the target site and other sites in the genome, thereby
reducing the possibility of off-target effects.
Researchers can request CRISPR/Cas targets obtained from their
own design preferences or they can take the help of Sigma's
expert CompoZr Zinc Finger Nuclease (ZFN) bioinformatics team to
produce a custom design based on cutting-edge public and
proprietary CRISPR guidelines.
ZFNs are the gold standard in gene technology and have been
instrumental in creating Sigma CRISPRs which provide researchers
a quicker and more affordable way to screen genes of
Sigma-Aldrich released its second quarter 2013 results in Jul.
The company posted adjusted earnings of $1.05 per share, above
the year-ago earnings of 97 cents. The results beat the Zacks
Consensus Estimate of $1.03. The adjusted earnings exclude other
charges of 7 cents a share.
Profit as reported, rose roughly 3.5% year over year to $119
million (or 98 cents per share) in the quarter from $115 million
(or 94 cents per share) a year ago.
Net sales increased 3% year over year to $681 million in the
reported quarter, surpassing the Zacks Consensus Estimate of $679
million. Organic sales growth in the quarter was 4%, while
foreign exchange translation had a negative impact of 1%.
Adjusted operating margin for the second quarter was 26.1%
compared with 25.8% recorded a year ago. Adjusted operating
margin in the reported quarter excludes other charges of $12
million related to merger/acquisition activity and settlement of
a licensing dispute.
Sigma-Aldrich currently maintains a Zacks Rank #3 (Hold).
Other companies in the specialty chemical space with favorable
Zacks Rank are
Minerals Technologies Inc.
Sensient Technologies Corp.
). While Ferro carries a Zacks rank#1 (Strong Buy), Minerals
Technologies and Sensient Technologies retain a Zacks Rank #2
FERRO CORP (FOE): Free Stock Analysis Report
MINERAL TECH (MTX): Free Stock Analysis
SIGMA ALDRICH (SIAL): Free Stock Analysis
SENSIENT TECH (SXT): Free Stock Analysis
To read this article on Zacks.com click here.